| Previous close | 7.75 |
| Open | 7.49 |
| Bid | 5.56 x 200 |
| Ask | 9.60 x 200 |
| Day's range | 7.49 - 7.81 |
| 52-week range | 7.11 - 15.49 |
| Volume | |
| Avg. volume | 40,438 |
| Market cap | 189.568M |
| Beta (5Y monthly) | 0.79 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.35 |
| Earnings date | 09 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 12.61 |
GlobeNewswireProfound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to Follow
TORONTO, April 22, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its first quarter 2024 financial results after market close on Thursday, May 9, 2024. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the
- GlobeNewswire
Profound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
TORONTO, April 09, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company’s business at the 2024 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 16, 2024 at 9:30 a.m. Eastern Time at the Metro Toronto Convention Centre.
Simply Wall St.Shareholders in Profound Medical (TSE:PRN) are in the red if they invested three years ago
If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. Long...
